Frequent loss of tumor suppressor ARID1A protein expression in adenocarcinomas/adenosquamous carcinomas of the uterine cervix

International Journal of Gynecological Cancer

Volumn 22, Issue 2, 2012, Pages 208-212

  Katagiri, Atsuko ^a   Nakayama, Kentaro ^a   Rahman, Mohammed Tanjimur ^a   Rahman, Munmun ^a   Katagiri, Hiroshi ^a   Ishikawa, Masako ^a   Ishibashi, Tomoka ^a   Iida, Kouji ^a   Otsuki, Yoshiro ^b   Nakayama, Satoru ^b   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

Author keywords

Adenocarcinoma adenosquamous carcinomas; ARID1A; Cervical carcinomas; Squamous cell carcinomas; Tumor suppressor gene

Indexed keywords

ADENINE THYMINE RICH INTERACTIVE DOMAIN 1A PROTEIN; KI 67 ANTIGEN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX ADENOSQUAMOUS CARCINOMA; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, ADENOSQUAMOUS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; JAPAN; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84858181873     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182313d78     Document Type: Article

References (21)

1. Jones SB. Cancer in the developing world: a call to action. BMJ. 1999;319:505-508. (Pubitemid 29391364)
2. Smith HO, Tiffany MF, Qualls CR, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year population-based study. Gynecol Oncol. 2000;78:97-105. (Pubitemid 30650338)
3. Chan PG, Sung HY, Sawaya GF. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. Obstet Gynecol. 2003;102:765-773. (Pubitemid 37206413)
4. Liu S, Semenciw R, Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ. 2001;164:1151-1152. (Pubitemid 34248394)
5. Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228-231.
6. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363:1532-1543.
7. Kuo KT, Mao TL, Chen X, et al. DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res. 2010;16:1997-2008.
8. Wang X, Nagl NG, Wilsker D, et al. Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. Biochem J. 2004;383:319-325. (Pubitemid 39446693)
9. Ho L, Crabtree GR. Chromatin remodelling during development. Nature. 463:474-484.
10. Van Rechem C, Boulay G, Leprince D. HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A. Biochem Biophys Res Commun. 2009;385:586-590.
11. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene. 2009;28:1653-1668.
12. Gao X, Tate P, Hu P, et al. ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. Proc Natl Acad Sci U S A. 2008;105:6656-6661. (Pubitemid 351754562)
13. Shepherd JH. Cervical and vulva cancer: changes in FIGO definitions of staging. Br J Obstet Gynaecol. 1996;103:405-406. (Pubitemid 26141629)
14. Nakayama K, Takebayashi Y, Hata K, et al. The proliferative activity of ovarian tumors of low malignant potential differs from that of ovarian carcinoma. Anticancer Res. 2003;23:4657-4662. (Pubitemid 38173881)
15. Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35:625-632.
16. Wiegand KC, Lee AF, Al-Agha OM, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=21590771. Accessed May 29, 2011.
17. Contag SA, Gostout BS, Clayton AC, et al. Comparison of gene expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Gynecol Oncol. 2004;95:610-617. (Pubitemid 39592529)
18. Schoolland M, Segal A, Allpress S, et al. Adenocarcinoma in situ of the cervix. Cancer. 2002;96:330-337.
19. Lea JS, Sheets EE, Wenham RM, et al. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol. 2002;84:115-119. (Pubitemid 34056476)
20. Nagl NG Jr, Patsialou A, Haines DS, et al. The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res. 2005;65:9236-9244. (Pubitemid 41507989)
21. Huang J, Zhao YL, Li Y, et al. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer. 2007;46:745-750. (Pubitemid 46912345)